Aclaris Therapeutics: Interesting Upside

"Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company's lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK), a non-malignant skin tumor. The Company has completed over three Phase II clinical trials of A-101 in over 300 patients with SK. The Company has initiated a Phase II clinical trial of A-101 for the treatment of common warts. In addition to A-101, the Company is also developing A-102, a topical gel dosage form of hydrogen peroxide, for the treatment of both SK and common warts. It has in-licensed the rights to inhibitors of the Janus kinase (JAK) family of enzymes, for specified dermatological conditions."

This is an interesting clinical stage company. I think its worth following and probably worth a small allocation. It could have upside if their clinical stage drugs actually prove successful and achieve FDA approval. It's hard to estimate what fair value of the stock should be, but the target market is big and in fact they focus on dermatology, which has a nice reputation for long lived products sold at decent prices to a wide audience.

Of course, it has zero revenues and so small size is appropriate here in terms of portfolio positioning.